RSV prevention market broadens as focus expands to high-risk children entering a 2nd season
The market for RSV prevention is expanding, with a focus on high-risk children entering their second season. While products like Sanofi's Beyfortus and MSD's Enflonsia target infants, Beyfortus currently holds a unique position for high-risk children in their second season.
Why it matters
The rapid growth of the RSV prevention market reflects a significant shift in pediatric healthcare toward proactive immunization for vulnerable populations.
As the market for respiratory syncytial virus (RSV) preventive antibody injections for infants and young children continues to expand, greater attention is shifting toward prevention strategies that cover not only infants entering their first RSV season but also high-risk children under the age of two entering their second season.
RSV is estimated to infect more than 90 percent of children before the age of two. Infants younger than six months are particularly vulnerable, as infection can progress to severe lower respiratory tract illnesses such as bronchiolitis and pneumonia, often requiring hospitalization. With no specific treatment available, prevention remains the primary strategy for reducing the disease burden.
The global market is also growing rapidly. According to Grand View Research, the market for RSV prevention options was valued at approximately $3.51 billion in 2024.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in